Sending Office: Honorable Linda T. Sanchez
Supported by: UsAgainstAlzheimer’s, Leaders Engaged on Alzheimer’s Disease, the Alzheimer’s Association, and the Alzheimer’s Impact Movement
Co-Sponsors 116th Congress: Reps. LaHood*, Matsui*, McMorris Rodgers*, Barragan, Cole, DeFazio, DelBene, Demings, Fitzpatrick, Grothman, Higgins, Kennedy, Khanna, Kuster, Lamb, Lewis, Lieu, Lofgren, Lowenthal, Mast, Napolitano,
Norton, Payne, Pocan, Posey, Raskin, Roybal-Allard, Scott (GA), Sires, Smith (NJ), Stevens, Upton, Waters
Co-Sponsors 115th Congress: Reps. Higgins, Johnson (GA), Kuster, Mast, Lowenthal, Blumenauer, Tonko, Cole, Fitzpatrick, Lujan, Bilirakis, Sires, Smith (NJ), Lofgren, Roybal-Allard, Raskin, Rooney, DeFazio, Lieu, Pocan,
I hope you will join in cosponsoring H.R. 2283, the Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act. This important bill will advance the diagnosis and treatment of Alzheimer’s disease and better support the caregivers of those
living with it.
An estimated 5.8 million Americans of all ages are living with Alzheimer’s in 2019. This year, Alzheimer’s and other dementias will cost the United States an estimated $290 billion, including $195 billion in Medicare and Medicaid payments (Alzheimer’s is
Medicare and Medicaid’s No. 1 cost driver).
By 2050, the number of people age 65 and older with Alzheimer’s may grow to a projected 14 million, and at the current rate, the cost of Alzheimer’s will reach $1.1 trillion in 2050.
While the latest emerging science indicates that proactive, risk-modifying measures exist and can strengthen brain health and increase resiliency against cognitive decline, Alzheimer’s remains the sixth-leading cause of death in the United States and the
only top-ten cause of death without an effective treatment or cure. Women and communities of color face higher risk for the disease and experience greater barriers to treatment, care, and research.
The CHANGE Act is a multipronged approach that encourages early assessment and diagnosis, relieves caregiver burden, and helps to accelerate progress to disease-modifying treatments. Our bill is a first step to drive synergies between high-value
patient care, caregiver support, brain health promotion, and research initiatives, which is our best hope for preventing, treating, and curing Alzheimer’s disease.
We can no longer wait. We urge you to join us in the fight against America’s biggest healthcare crisis by cosponsoring and supporting this important bill. The time to act is now. If you have questions or would like to cosponsor this bill, please contact
Laila Goharioon with Rep. Sánchez.
Linda T. Sánchez
Member of Congress
e-Dear Colleague version 2.0